

1 **Experimental glaucoma retinal proteomics identifies mutually exclusive and**
2 **overlapping molecular characteristics with human glaucoma**

3

4 Mehdi Mirzaei^{1,2,3} ❖, Vivek Gupta² ❖, Nitin Chitranshi² ❖, Liting Deng¹, Kanishka
5 Pushpitha², Mojdeh Abbasi², Joel Chick⁴, Rashi Rajput², Yunqi Wu^{1,3}, Matthew. J.
6 McKay^{1,3}, Ghasem H Salekdeh⁵, Veer Gupta⁶, Paul A. Haynes¹, Stuart L. Graham²

7

8

9 ¹Department of Molecular Sciences, Macquarie University, Sydney Australia

10 ²Department of Clinical Medicine, Macquarie University, Sydney Australia

11 ³Australian Proteome Analysis Facility, Macquarie University Sydney Australia

12 ⁴Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA

13 ⁵Department of Molecular Systems Biology, Cell Science Research Center, Royan,
14 Institute for Stem Cell Biology and Technology, ACECR Tehran Iran

15 ⁶School of Medicine, Deakin University, Melbourne Australia

16

17 ❖ Authors contributed equally to work

18

19

20 **Correspondence:**

21 Mehdi Mirzaei

22 Email: mehdi.mirzaei@mq.edu.au

23 Australian Proteome Analysis Facility|

24 Macquarie University | NSW 2109, Australia

25 Tel: +61 2 98508284

26

27 Vivek Gupta

28 Email: vivek.gupta@mq.edu.au

29 Faculty of Medicine and Health Sciences |

30 Macquarie University | NSW 2109, Australia

31 Tel: +61 9850 2760

32

33 **Abstract**

34 Current evidence suggests that exposure to chronically induced intraocular pressure
35 (IOP) leads to neurodegenerative changes in the inner retina. This study aimed to
36 determine retinal proteomic alterations in a rat model of glaucoma and compared
37 findings with human retinal proteomics changes in glaucoma reported previously. We
38 developed an experimental glaucoma rat model by subjecting the rats to increased IOP
39 (9.3 ± 0.1 vs 20.8 ± 1.6 mm Hg) by weekly microbead injections into the eye (8 weeks).
40 The retinal tissues were harvested from control and glaucomatous eyes and protein
41 expression changes analysed using multiplexed quantitative proteomics approach.
42 Immunofluorescence was performed for selected protein markers for data validation.
43 Our study identified 4304 proteins in the rat retinas. Out of these, 139 proteins were
44 downregulated (≤ 0.83) while expression of 109 proteins was upregulated (≥ 1.2 -fold
45 change) under glaucoma conditions ($p \leq 0.05$). Computational analysis revealed reduced
46 expression of proteins associated with glutathione metabolism, mitochondrial
47 dysfunction/oxidative phosphorylation, cytoskeleton and actin filament organisation,
48 along with increased expression coagulation cascade, apoptosis, oxidative stress and
49 RNA processing markers. Further functional network analysis highlighted the
50 differential modulation of nuclear receptor signalling, cellular survival, protein
51 synthesis, transport and cellular assembly pathways. Alterations in crystallin family,
52 glutathione metabolism and mitochondrial dysfunction associated proteins shared
53 similarities between the animal model of glaucoma and the human disease condition.
54 In contrast, the activation of the classical complement pathway and upregulation of
55 cholesterol transport proteins, were exclusive to the human glaucoma. These findings
56 provide insights into the neurodegenerative mechanisms that are specifically affected
57 in the retina in response to chronically elevated IOP.

58

59

60 **Keywords:** Glaucoma, Neurodegeneration, Proteomics, Retina

61 **1 Introduction**

62 Glaucoma is a common neurodegenerative disease of the retina and is considered as a
63 leading cause of irreversible blindness in the elderly population worldwide. Even
64 though the exact pathophysiology of the disease remains incompletely understood, its
65 association with increased intraocular pressure (IOP) and correlation with the retinal
66 ganglion cell (RGC) death, as well as degeneration of their axons in the optic nerve, is
67 well established [Chitranshi et al., 2018a].

68 Apart from mechanical or vascular effects of increased IOP, other complex risk factors
69 have increasingly have been associated with the disease onset and progression,
70 including family background, lifestyle, genetics, inflammation, epigenetic factors,
71 secondary neurodegenerative effects of brain disorders, and old age progression
72 [McMonnies, 2017]. Currently, the primary approach to slow down the progression of
73 glaucoma is through reducing the IOP. Nevertheless, thinning of nerve fibre layer and
74 progression of visual field defects continue to be widely reported in the glaucoma
75 patients treated for IOP reduction. This suggests other mechanisms contribute to the
76 disease pathogenesis and progression. There are patients, on the other hand, who exhibit
77 clinical presence of high IOP without corresponding evidence of anatomical or
78 functional damage to the visual system, indicating that elevated IOP may only
79 constitute one of the several variables in the complex pathogenesis of glaucoma [Kass
80 et al., 2002]. To make further advances in glaucoma diagnosis and develop alternative
81 therapeutics, there is a need to systematically define the mechanisms underlying
82 glaucoma. Distinguishing the molecular effects of IOP elevation from a more complex
83 human glaucoma condition, where several other factors might be involved, will help in
84 greater understanding of the disease process.

85 We recently carried out a comprehensive proteomics study in the post-mortem retinas
86 from human POAG subjects and demonstrated that the pathology is associated with
87 oxidative stress, mitochondrial dysfunction, dysregulation of immune response,
88 disruption of neurotrophic factors and apoptosis activation in the retina [Mirzaei et al.,
89 2017a]. Other proteomics studies in human tissues and animal models have indicated
90 oxidative modification and other post-translational changes in various molecules
91 [Bhattacharya et al., 2006; Tezel et al., 2005]. Enrichment of TNF α signalling pathways
92 and mediation of immune response have also been suggested to play a role in the disease
93 spectrum [Tezel, 2013; Tezel, 2014]. Funke et al. (2016) identified about 600 proteins
94 from the glaucoma and control human retinal tissues using a label free quantitative

95 proteomics approach [Funke et al., 2016]. Proteomics analysis of the non-human
96 primate retinas subjected to experimental glaucoma and optic nerve transection
97 revealed protein changes with little overlap between the two conditions, indicating that
98 mechanisms of RGC damage under these two experimental conditions can be
99 completely different [Stowell et al., 2011]. Andres et al (2017), using the same label-
100 free proteomics technique in an episcleral vein cauterization model, identified 931
101 proteins that were altered in early phases of IOP increase [Anders et al., 2017]. These
102 studies provided critical insights into the molecular pathogenesis of the disease,
103 however, the latest proteomics technological advances in instrumentation, sample
104 processing and preparation, and bioinformatics analysis tools have enabled us to
105 achieve deeper proteome coverage. In this study, we carried out multiplexed proteomics
106 using TMT SPS-MS3 method and identified about <4300 proteins in the retinas of
107 microbead induced rat model of experimental glaucoma. This is a widely used chronic
108 model of experimental glaucoma and our data reflects that pathways linked to
109 mitochondrial function, cytoskeletal organisation and glutathione metabolism were
110 negatively affected while proteins linked to oxidative stress and apoptotic processes
111 were increased in expression. We analysed this data in the light of previously reported
112 human glaucoma induced changes in the retina and vitreous [Mirzaei et al., 2017a] and
113 this approach permitted us to establish the unique and shared proteins and pathways
114 that are differentially affected under glaucoma conditions.
115 Identification of these proteins and molecular networks is essential to understand the
116 disease pathophysiology as well as develop target-based drugs and biomarkers for
117 diagnostic applications. This data will serve as an important resource for glaucoma
118 research and will help in comparing the proteomics changes in the retinas of microbead
119 induced chronically increased IOP model with multifactorial human glaucoma
120 condition.

121

122

123 **2 Results**

124 ***2.1 Quantitative analysis of retinal proteome using multiplexed TMT***

125 A total of 4304 reproducible proteins were identified and quantified from the retinal
126 tissue (1% FDR) - see table 1 (<https://data.mendeley.com/research-data/>). The quality
127 of the data and reproducibility of the biological replicates across groups were assessed
128 using hierarchical clustering and statistical metrics. We observed great similarity in
129 overall protein abundance distributions of individual biological replicates of both
130 control and glaucoma conditions, confirming the reproducibility of the data for further
131 analysis (Figure 2A). To identify the differentially proteins between glaucoma and
132 control conditions, student's *t-test* was carried out. Proteins that met the *p*-value cut-off
133 (≤ 0.05) and at least 20% difference (Table 1) were considered as differentially
134 modulated proteins. This two-step differential analysis of high IOP vs control retinas
135 yielded 139 down regulated ($p\text{-value} \leq 0.05$ and ≤ 0.83 -fold change) and 109 up-
136 regulated ($p\text{-value} \leq 0.05$ and ≥ 1.2 -fold change) proteins (Fig 2A, B). A list of top 50
137 up- and down regulated proteins including their fold changes and their interaction
138 network with *p*-value cut-off are shown in Fig. 2C, D. Several members of the crystallin
139 family (aa, ba1, ba2, ba4, bb1, bb2, bb3, γ s), as well as other proteins including
140 S100a10, S100a4, AHNAK, ANXA1, APOE, CSTS among others were prominently
141 decreased while the expression of coagulation associated proteins including FGG,
142 FGA, FGB, KNG1 and KNG2 were increased in high IOP exposed retinas (Fig. 2C,
143 D).

144

145 ***2.2 Differentially regulated cellular pathways and protein networks in glaucomatous*** 146 ***retinas***

147 To visualize the protein interaction and networks among these differentially modulated
148 proteins, we generated the retinal protein networks using the STRING and Cytoscape
149 protein-protein interaction analysis tools. From 248 differentially expressed proteins,
150 21 separate interconnected networks (Fig 3) were identified. Several molecular
151 pathways were reduced in expression, including those involved in actin filament
152 organisation, protein folding, cytoskeleton arrangement, calcium binding, oxidative
153 phosphorylation, and glutathione metabolism. Other networks were increased in
154 expression, such as coagulation, apoptosis and oxidative stress and cell signalling (Fig
155 3). We performed cellular pathway enrichment and functional protein network analyses

156 on the 248 differentially expressed proteins to understand the molecular mechanisms
157 and biological processes that are altered in the retina in response to exposure to
158 increased IOP. Analysis of the differentially regulated proteins using Ingenuity
159 Pathway Analysis (IPA) revealed that the top enriched disease and implicated
160 biological functions were associated with pathways linked with neurodegenerative
161 processes, modulation of nuclear receptors such as RAR and RXR, Tec kinase and
162 interleukin signalling, mitochondrial dysfunction, fatty acid oxidation and acute phase
163 response signalling (Fig. 4). Overall, the combination of canonical IPA pathway and
164 STRING/ Cytoscape protein-protein network analysis allowed us to visualize the most
165 significantly differentially affected biological processes in the retina of experimental
166 glaucoma model.

167

168 ***2.3 Redox regulation and oxidative phosphorylation in glaucoma***

169 Mitochondrial dysregulation and impaired oxidative phosphorylation have been
170 implicated strongly in glaucoma pathogenesis [Lee et al., 2011]. A major role of
171 mitochondria is the generation of ATP through oxidative phosphorylation and the
172 regulation of cell death by apoptosis [Hüttemann et al., 2007; Kong et al., 2009]. High
173 energy requirements of the RGCs make them particularly susceptible to anomalies
174 associated with mitochondrial function. We observed reduced abundance of
175 mitochondrial ATP synthase (ATP 5E) and V-type proton ATPase (ATP6v1g1). The
176 oxidative phosphorylation and mitochondrial proteins COX1, Pcd5, Tgm2 and
177 Ndufa2 were also identified in the list of differentially expressed proteins in glaucoma
178 condition (Fig. 3). It is well documented that IOP increase in glaucoma induces
179 oxidative stress in RGCs through reduced activity of key antioxidant enzymes (e.g;
180 glutathione peroxidases) which are responsible for fighting against oxidative stress
181 [Moreno et al., 2004]. Stress associated proteins such as glutathione metabolic proteins,
182 which are involved in mediating protection of cells against oxidative stress by
183 neutralising highly reactive free radical species, namely GPX1, GSS, GSTM1/2, were
184 significantly downregulated while GSTT3 was observed to be upregulated in glaucoma
185 retinas. Mitochondrial impairment may alter NADPH levels and has been shown to
186 contribute to dysregulated oxidoreductase activity in the cells. In this study we
187 identified that the retinal tissues exposed to high IOP demonstrated reduced levels of
188 aldose reductase (Akr1b1), aldehyde dehydrogenase (Aldh1a1, Aldh2), enolase
189 (Enoph1), acyl dehydrogenase (Hadh) and phosphoglycerate dehydrogenase (Phgdh)

190 enzyme subunits. We also observed upregulation of carbonic anhydrase (Car1), retinal
191 dehydrogenase (RDH12), protein kinase C (Prkce) and NAD dependent 17 β -
192 dehydrogenase (Hsd17b8) enzymes (Fig. 3). These proteins are involved in regulating
193 oxidoreductase activity and NAD binding suggesting that these pathways were
194 negatively impacted in the retinas in response to chronic exposure to high IOP (Fig. 3
195 and Table 1).

196

197 ***2.4 Effects of glaucoma on actin filament organisation and cytoskeletal dynamics***

198 The internal scaffolding of cells is affected in glaucoma with trabecular meshwork,
199 optic nerve and lamina cribrosa exhibiting profound reorganisation of the actin filament
200 networks [Clark et al., 1995; Hoare et al., 2009; Job et al., 2010]. The internal
201 architecture is particularly important to maintain the biomechanical properties and
202 axonal support. We observed consistent downregulation of the proteins associated with
203 actin skeletal organisation and protein folding in the retina under glaucomatous
204 conditions. We identified 9 members of the crystallin family that were downregulated
205 in glaucoma condition (Cryaa, Cryba2, Crygs, Cryab, Crybb1, Cryba4, Cryba1,
206 Crybb2, Crybb3) (Fig. 3, Fig. 5, Fig 6). Crystallins are primarily heat shock proteins
207 that are involved in regulating the actin and intermediate filament
208 cytoskeleton dynamics and protect the cells against stress [Launay et al., 2006].
209 Reduced levels of Connexin 50 (Gja8) and Griffin cell junction proteins that are
210 involved in mediating cell-cell interactions and cytoskeletal binding were observed in
211 the retinal tissues subjected to high IOP. Our proteomics datasets also included proteins
212 associated with cytoskeleton arrangement and protein folding. Tropomyosin isoforms
213 (Tpm1, Tpm3, Tpm 4), which are considered primary regulators of F-actin
214 cytoskeleton, were downregulated in the retinas under glaucomatous conditions. As a
215 matter of interest, pseudokinase Camkv, that may act as scaffold and spatial anchor for
216 cytoskeletal proteins and is also involved in dendrite physiology, was prominently
217 upregulated in the retinas [Jacobsen and Murphy, 2017]. Similarly, Calml3 and Coro1a
218 were overexpressed under the glaucomatous conditions; Calml3 has previously been
219 shown to be differentially regulated in POAG [Liu et al., 2013].

220

221 ***2.5 Impaired RNA metabolism and SNARE complex machinery***

222 RNA metabolism was another major cellular process that was impacted in the retinas
223 exposed to glaucomatous injury. We identified six upregulated and six downregulated

224 proteins that have previously been implicated in regulating RNA metabolism,
225 suggesting that RNA processing was negatively impacted. Atg7 has been shown to
226 mediate axonal preservation [Komatsu et al., 2007] and was overrepresented in
227 glaucomatous retinas. Stat5a levels were also enhanced in response to high IOP injury,
228 which corroborates the previous reports of increased levels of Stat5a mRNA in RGCs
229 in response to experimental glaucoma [Wang et al., 2010]. Igfbp7 levels, in contrast,
230 were significantly downregulated under high IOP. This protein has also been shown to
231 be suppressed in response to hypoxia in the retinas in a mouse model of oxygen induced
232 retinopathy [Ishikawa et al., 2010].

233 In addition to the RNA metabolism, our data suggests significant perturbation of
234 SNARE machinery associated proteins that regulate formation of membrane vesicles
235 as well as the timing and specificity of vesicular fusion [Manca et al., 2019; McKay et
236 al., 2013]. Myocilin has been suggested as a part of the SNARE like complex based on
237 its homology with Q- SNAREs [Dismuke et al., 2012]. We identified 9 proteins
238 associated with the intracellular SNARE transport complex to be differentially
239 regulated in the retinas of high IOP exposed animals. Sec23b and Stx5 proteins which
240 are involved in ER-Golgi transport [Liang et al., 2018] were observed to be upregulated
241 (Fig. 3). On the other hand, Importin proteins (IPO5 and 9), that mediate energy
242 dependent transportation through the nuclear pore, were downregulated [Alqawlaq et
243 al., 2012] along with other SNARE proteins such as Cops8, Cplx2, Gorasp2, Manf and
244 Stx4. Perturbations in SNARE machinery might play a role in dysregulation of
245 intracellular processes including autophagosome fusion with lysosomes, leading to
246 impaired cargo transport and recycling, which are pathological processes implicated in
247 glaucoma [Frost et al., 2014; Porter et al., 2013; Swarup and Sayyad, 2018].

248

249 ***2.6 Molecular overlap of protein networks in human and experimental glaucoma***

250 The rat experimental glaucoma data obtained in this study was compared with our
251 previously published [Mirzaei et al., 2017a] retinal and vitreous proteomics data from
252 human POAG tissues. Pathway analysis revealed 65 proteins that were common
253 between the two sets and differentially modulated. A majority of the common
254 differentially expressed proteins were downregulated under both these conditions.
255 Overall, fifty proteins shared a similar expression pattern, amongst these 41 were down-
256 and 9 up- regulated across both systems. Further analysis indicated that within the
257 downregulated set, 9 proteins belonged to the crystallin family that is associated with

258 protein folding (Cryaa, Cryba2, Crygs, Cryab, Crybb1, Cryba4, Cryba1, Crybb2,
259 Crybb3), 3 members to glutathione synthesis pathway (gss, gstm1, gstm2), two were
260 Annexin proteins (anaxa6, anaxa1), and two were S100 proteins (s100a4, s100a10)
261 (Fig. 5A, B). To explore the differential regulation of crystallins, which was identified
262 as one of the most prominent protein groups modulated across rat and human data sets,
263 we subjected both rat and human retinal sections to immunofluorescence analysis using
264 selected crystallin antibodies ($\alpha\beta$, β B2 and β B3) (Fig. 6). The results validated our MS
265 findings and demonstrated noticeable downregulation of expression of each of these
266 isoforms in glaucoma conditions. The downregulation was particularly localised to the
267 GCL in the inner retina, a region that is preferentially affected in glaucoma. The shared
268 up-regulated proteins included glycoprotein m6a (gpm6a), glycoprotein m6b (gpm6b),
269 synaptic vesicle glycoprotein 2A (sv2), DmX-like protein 2 (dmxl2), C-terminal-
270 binding protein 2 (ctbp2), G Protein Subunit β 3 (gnb3), carbonic anhydrase 1 (ca1),
271 retinoschisin (rs1), and coronin1A (coro1a) (Fig. 5A). However, this also means that a
272 substantial number of uniquely affected pathways were also identified in both the
273 human and rat experimental glaucoma conditions. Another noticeable observation in
274 these sets was with respect to the 15 proteins that were differentially modulated but
275 followed an opposite pattern of abundance. Prominent amongst these were fibrinogen
276 subunit (fgg), c-reactive protein (crp), proteasome activator (psme2) and apolipoprotein
277 E, listed in 5A. With this approach, we noted shared differential regulation of proteins
278 implying similar changes in both the data sets in molecular pathways that are involved
279 in mediating retinal structure and development, ageing, apoptotic processes and
280 regulating axonal health. (Fig. 5B).

281

282 **3 Discussion**

283 This study aimed to investigate the molecular basis of glaucoma pathogenesis by taking
284 a systems-level perspective of the experimental glaucoma retinal proteome in
285 microbead model using an unbiased quantitative proteomics approach. We analysed
286 molecular similarities and difference between a glaucoma model and the human POAG
287 condition, by comparing the animal retinal proteome against our previously published
288 human data [Mirzaei et al., 2017a]. To our knowledge, this is the most comprehensive
289 retinal proteome profile in a chronic model of experimental glaucoma, and provides
290 validation of several protein markers recently identified in human glaucoma tissues
291 [Mirzaei et al., 2017a]. Over 4300 proteins were identified with expression of 248

292 proteins differentially modulated in retina in response to sustained exposure to
293 increased IOP. The study revealed that key pathways involved in cellular stress and
294 tissue homeostasis were affected in the retina under high IOP conditions. Using a
295 combination of functional pathway and protein-protein interaction analysis tools
296 enabled us to identify the specific pathways, which were down regulated or induced in
297 animal model of high IOP. In agreement with human data, this study revealed down
298 regulation of proteins associated with oxidative phosphorylation, glutathione
299 biosynthesis, protein folding, actin filament organisation, and cytoskeleton protein
300 networks. Coagulation cascade was amongst the mutually upregulated pathways in both
301 human and animal model. In accordance with the complex nature of human glaucoma
302 condition, the study revealed that a large series of biochemical pathways were affected
303 in the human glaucoma retina in contrast to the high IOP exposed rat model.

304 In this study, we identified 11 members of crystallin family as significantly down
305 regulated in glaucoma samples. All these crystallins were embodied in the top 50 down
306 regulated proteins as presented in figure 2C. The STRING protein interaction analysis
307 revealed that crystallins are associated with actin filament organisation and protein
308 folding biological processes. Crystallins belong to the family of small heat shock
309 proteins and consist of three main sub families (α , β , and γ crystallins), which are
310 expressed in RGCs [Liedtke et al., 2007; Piri et al., 2007]. Of these 11 proteins, 6
311 belonged to the β (CRYBA1, CRYBA2, CRYBA4, CRYBB1, CRYBB3, CRYBB2,
312 CRYBB1), 3 to α (CRYAA, CRYAA-isoform 2 and CRYAB) and 2 to the γ family
313 (CRYGN and CRYGS). Differential expression of crystallins has been reported in
314 number of neurodegenerative disorders including glaucoma [Piri et al., 2007; Prokosch
315 et al., 2013]. Human glaucoma patients have been reported to exhibit increased titer
316 values of antibodies against small HSPs [Tezel et al., 1998]. Crystallins play a role as
317 a molecular scaffold and potential modulator of important signalling molecules in
318 glaucoma, and thus are integral to the process of glaucomatous neurodegeneration
319 [Tezel et al., 1998]. Immunofluorescence analysis of the crystallin expression changes
320 revealed a consistent downregulation of various crystallin isoforms in both rat and
321 human tissues. This downregulation was particularly localised to the GCL region and
322 indicates that crystallin changes in glaucoma are likely induced by exposure to
323 chronically elevated IOP.

324 In addition to the crystallins, another network associated with cytoskeleton and protein
325 folding that was differentially modulated was the down regulation of 3 tropomyosin

326 members (TPM1, TPM3 and TPM4) along with reduction in protein levels of TUBB6,
327 VBP1, PFDN2, IQGAP2, ARVCF and AHNAK. In contrast, cytoskeletal proteins such
328 as CORO1A and DNAH7, and signalling proteins such as AKTIP, CAIM3 and
329 CAMKV were up regulated. This is consistent with previous studies that have indicated
330 reduction in the levels of Camkv protein in rat model of ischemia reperfusion injury
331 [Tian et al., 2014].

332 Besides modulation of heat shock and cytoskeletal proteins, Ca²⁺ binding proteins such
333 as S100A10, S100, FBN1 and LGALS1 were identified to be downregulated and these
334 proteins interact with other downregulated proteins such as ANAX6, ANAX1, APOE,
335 NEK9, MFAP2, and HSPG2. This interconnected network was largely downregulated,
336 however, synaptic vesicle glycoproteins 2A and 2C, that have a direct interaction with
337 HSPG2, and KNG1 that interacts with Anxa1, were significantly enriched.

338 Increased expression of proteins associated with coagulation cascade (FGG, FGB and
339 FGA) was also evident in glaucomatous retinas. Activation of coagulation cascade is
340 associated with inflammatory processes in a number of neurodegenerative diseases,
341 including glaucoma. The mechanisms by which the coagulation system is altered
342 comprises enhanced synthesis and activation of coagulant proteins, decreased synthesis
343 of anticoagulants, and suppression of fibrinolysis. However, not only does
344 inflammation activate coagulation, but this may lead to a vicious cycle, where
345 coagulation in turn perpetuates inflammatory response [Levi and van der Poll, 2010].

346 A prominent downregulation of oxidative phosphorylation enzymes was detected in the
347 rat retinas, similar to the mitochondrial suppression demarcated by downregulation of
348 electron transport chain and mitochondrial ribosomal proteins reported in human
349 glaucoma tissues [Mirzaei et al., 2017a]. Mitochondrial compromise has been
350 extensively reported in animal models and in human glaucoma condition
351 [Chrysostomou et al., 2013; Munemasa et al., 2010]. RGCs, being metabolically highly
352 active, constitute a cell population that is decidedly susceptible to mitochondrial failure.
353 Modulating mitochondrial integrity, such as by inducing DRP1 inhibition or CoQ₁₀
354 treatment, has been shown to rescue RGCs in glaucoma [Kim et al., 2015; Lee et al.,
355 2014; Lee et al., 2011]. Mitochondrial dysfunction, in turn, affects the NAD/NADH
356 levels and here we observed downregulation of certain key redox regulatory enzymes
357 in response to high IOP exposure, such as aldehyde dehydrogenase, enolase, aldose
358 reductase, acyl dehydrogenase, and phosphoglycerate dehydrogenase. We have
359 previously reported downregulation of 13 subunits of the NADH dehydrogenase:

360 ubiquinone oxidoreductase complex 1 in the human POAG, and these findings together
361 may reflect a failure of the tissues to maintain redox homeostasis in glaucoma. Williams
362 et al. (2017) demonstrated that administration of the NAD precursor niacin, and gene
363 therapy driving expression of *Nmnat1*, a key NAD⁺-producing enzyme, modulated
364 mitochondrial vulnerability and prevented experimental glaucoma in ageing animals
365 [Williams et al., 2017].

366 In a network associated with ion transport across membranes, 3 members of the SLC4
367 gene family were upregulated in glaucoma; SLC4A2, SLC4A3 and SLC4A5. The
368 modulation of the SLC4 gene family has been linked to ocular and corneal diseases in
369 humans. Mutations in SLC4A4 in addition to their role in renal acidosis are implicated
370 in ocular anomalies including glaucoma [Horita et al., 2018]. Furthermore, 3 proteins
371 associated with apoptotic pathways (BIRC6, TRAF3 and TNIK) were recognized as
372 enriched in glaucoma conditions. BIRC6 protein (baculovirus IAP repeat containing
373 protein 6) is a member of the inhibitor of apoptosis gene family, which encodes
374 negative regulatory proteins that play a preventative role in apoptotic cell death. The
375 proteolytic activity of caspases is tightly controlled by the family of inhibitors of
376 apoptosis which are normally induced in the chronic inflammation in cancers and
377 neurodegenerative diseases. TRAF proteins are essential components of signalling
378 pathways activated by TNFR or Toll-like receptor family members. TRAF3 is reported
379 to be a highly versatile regulator that positively controls type I interferon production,
380 but negatively regulates MAP kinase activation and alternative nuclear factor- κ B
381 signalling [Cai et al., 2013]. TNIK, in contrast, is a member of the germinal center
382 kinase family, and is widely involved in cytoskeleton organization, neuronal dendrite
383 extension, cell proliferation, and glutamate receptor regulation. Notably, an emerging
384 body of evidence suggests that TNIK is a novel activator of Wnt signalling [Yu et al.,
385 2014], and the Wnt pathway plays critical roles in the regulation of many cellular
386 functions, including cellular proliferation, differentiation, migration, and maintenance
387 of pluripotency. However, although GWAS linked variants have been reported with
388 respect to TNIK [Zagajewska et al., 2018]; to our knowledge, changes in regulation of
389 TNIK protein has not been reported in any previous glaucoma study.

390 In this report, we have shown that high IOP subjected rat retinas demonstrated shared
391 components of several tissue stresses, and adaptive or neuroprotective responses that
392 were also identifiable in human glaucoma subjects [Mirzaei et al., 2017a]. Notably,
393 many biochemical networks such as modulation of cholesterol transport proteins and

394 classical complement activation were uniquely affected in the human eyes [Mirzaei et
395 al., 2020]. It is important to emphasise that the responses detected in rat retinas were
396 caused by IOP increase alone without any underlying manifest neurodegenerative or
397 vascular pathology. This is a limitation of the current glaucoma models being used in
398 research, nevertheless, the molecular data helps to dissect various components of the
399 glaucoma pathology as a complex neurodegenerative/ vascular disorder. In this study
400 we have analysed the proteome of the whole retinal tissues, which limits our ability to
401 distinguish the individual contribution of distinct cell types that comprise the retina.
402 This limitation has been extensively discussed in our previous study analysing the
403 human glaucoma retinal tissues [Mirzaei et al., 2017a]. Further, a different
404 experimental design in which animal retinal tissues are harvested at intermediate time
405 points will help us understand the chronology of biochemical changes that occur in
406 response to chronically elevated IOP exposure.

407 In conclusion, the proteomics data provides new insights into a purely high IOP induced
408 scenario for retinal changes, without the complex interplay of ageing, genetic or
409 systemic factors and drug effects, which are inevitable confounding variables in human
410 cohort studies. Future research will help elucidate the individual effects of various risk
411 factors in glaucoma, to help us better understand the disease process and thereby
412 develop new therapeutic strategies.

413

414 **4 Material and Methods**

415 **4.1 Animals**

416 Adult male Sprague-Dawley rats (n=10) were used for the experiments (High
417 IOP/glaucoma: 5, control: 5). All animals were maintained at controlled temperature
418 ($21 \pm 2^\circ\text{C}$) for 12-hour light/dark cycles. All procedures were performed in accordance
419 with the Australian Code of Practice for the Care and Use of Animals for Scientific
420 Purposes and the guidelines of the ARVO Statement for the Use of Animals in
421 Ophthalmic and Vision Research. The animals were subjected to anaesthesia using
422 intraperitoneal (i.p.) administration of ketamine (75 mg/kg) and medetomidine (0.5
423 mg/kg)[You et al., 2012] for the microbead injections[Chitranshi et al., 2018b].

424

425 **4.2 Intra-ocular injections and pressure measurements**

426 An experimental glaucoma model was established by producing a chronic increase of
427 intra-ocular pressure (IOP) in mice by microbead (Fluospheres, Molecular Probes, 10

428 μm) injections in the anterior chamber as reported previously [Chitranshi et al., 2019;
429 Gupta et al., 2014; You et al., 2014]. Intraocular injections (3.6×10^6 microbeads/mL)
430 in the anterior chamber of the eye were performed until a sustained increase in IOP was
431 observed. Eyes were injected using a 25- μL Hamilton syringe connected to a disposable
432 33-gauge needle (TSK, Japan). All intracameral procedures were performed under
433 magnification using an operating microscope (Carl Zeiss, Germany) with care taken to
434 avoid needle contact with the iris or lens. The needle was inserted bevel down,
435 tangentially beneath the corneal surface, to facilitate self-sealing of the puncture
436 wound. Once the needle tip was visualised within the anterior chamber, 2 μL microbead
437 solution was injected. At the end of the procedure, anaesthesia was reversed using
438 atipamazole (0.75 mg/kg subcutaneous injection, and 0.3% ciprofloxacin drops
439 (Ciloxan; Alcon, Australia) and 0.1% dexamethasone eye drops (Maxidex, Alcon) were
440 instilled in both eyes. An ointment (Lacri-lube; Allergan, Australia) was also applied
441 to protect against corneal drying until the animal recovered. During anaesthesia and
442 prior to each injection, IOP was measured by using a handheld electronic tonometer
443 (Icare Tonovet, Finland). The IOP displayed on the tonometer was the mean of six
444 consecutive measurements. Three consecutive IOP readings were obtained from each
445 eye and the average number was taken as the IOP for that time point.

446

447 **4.3 Preparation of protein samples**

448 The retinas of experimental glaucoma (n=5) and control animals (n=5) were extracted
449 from the eyes using the surgical microscope. Protein extraction was carried out using
450 lysis buffer (20 mM HEPES, pH 7.4, 1% Triton X-100, 1 mM EDTA) containing
451 protease and phosphatase inhibitors. Samples were subjected to probe sonication (3
452 pulses/15s with 20s between each pulse). Lysed samples were centrifuged (15,000 g
453 for 10 min at 4°C) and protein in the supernatant concentrated by precipitation using a
454 chloroform methanol precipitation procedure [Wessel and Flügge, 1984]. Precipitated
455 protein was resuspended in 200 μL of 8M Urea in 50 mM Tris (pH 8.8). Protein
456 concentration was determined using a BCA assay (Pierce, Rockford, USA) and bovine
457 serum albumin (BSA) as a standard. Solubilised proteins were reduced using 5mM
458 DTT and alkylated using 10mM iodoacetamide. Proteins (150 μg) were initially
459 digested at room temperature overnight using a 1:100 enzyme-to-protein ration using
460 Lys-C (Wako, Japan), followed by digestion with Trypsin (Promega, Madison, WI) for
461 at least 4 hours at 37 °C also at a 1:100 enzyme-to-protein ratio.. Resultant peptides

462 were acidified with 1% TFA and purified using SDB-RPS (Empore) Stage Tips [Kulak
463 et al., 2014].

464

465 ***4.4 TMT labelling and liquid chromatography electrospray ionization tandem mass*** 466 ***spectrometry (LC-ESI-MS/MS)***

467 Details of the 10 plex TMT experimental workflow are shown in figure 1. Briefly,
468 peptides (70 µg) from each retinal sample were subjected to TMT labelling as outlined
469 in our previous study on human glaucoma retinal tissues [Mirzaei et al., 2017a]. Briefly,
470 pooled and labelled peptides were separated into 12 fractions following HpH
471 chromatography and dried by vacuum centrifugation. Peptide fractions were analysed
472 by nano-LC-MS/MS using an ultra-high-pressure liquid chromatography system
473 (Proxeon) and an Orbitrap Fusion Tribrid-MS (Thermo Scientific, USA) mass
474 spectrometer. Peptide fragmentation was performed using the (SPS)-MS³ method
475 described previously [McAlister et al., 2014].

476 ***4.5 Database searching/quantification and statistical analysis***

477 Charge state and monoisotopic m/z values were corrected using a method previously
478 detailed by Huttlin et al [Huttlin et al., 2015]. Spectra were search against an indexed
479 *Rattus norvegicus* Uniprot database using the Sequest search algorithm and included
480 carbamidomethylation of cysteine residues, and TMT labelling of peptide N-termini
481 and lysine residues as static modifications, oxidation of methionine as a dynamic
482 modification, and a precursor ion tolerance of 20 ppm and fragment ion tolerance of
483 0.8 Da. A linear discriminant analysis was used to filter Sequest matches to a false
484 discovery rate (FDR) of 1% at the peptide level based on matches to reversed sequences
485 [Elias and Gygi, 2010]. Protein were ranked by multiplying peptide probabilities and
486 the dataset was finally filtered to 1% protein FDR. TMT reporter ion quantification was
487 assessed using the strategy described previously [Chick et al., 2016; McAlister et al.,
488 2012]. Peptides with a total signal-to-noise (S/N) for all channels of >200 with a
489 precursor isolation specificity of >0.75 were used for quantification. TMT reporter ion
490 intensity values were normalized by summing values across all peptides within each
491 channel then correcting each channel to the same summed value. Protein level
492 quantification was performed using normalized S/N values for all peptides assigned to
493 a given protein. Differentially expressed proteins were assessed using a two-sample t-
494 test ($p \leq 0.05$) and a fold change threshold (≥ 1.2 for up-regulation or ≤ 0.83 for down-

495 regulation). Reproducibility of the TMT experiment was evaluated further using our in-
496 house ‘TMTPrepPro’ software reported previously [Mirzaei et al., 2017b].

497

498

499 ***4.6 Bioinformatics and functional pathway analysis***

500 Functional pathway enrichment and protein-protein interaction analysis of
501 differentially modulated proteins were performed using Ingenuity pathway analysis
502 (IPA) and STRING protein-protein network analysis [Szklarczyk et al., 2015] as
503 described previously [Mirzaei et al., 2017a]. For Ingenuity, the canonical pathway
504 analysis highlighted the function-specific genes present in each networks. STRING
505 Cytoscape plug-in assisted in detecting the protein-protein interactions as well as
506 classifying the differentially modulated pathways and networks.

507

508 ***4.7 Tissue Sectioning and Immunofluorescence Analysis***

509 Rats eyes were enucleated following the transcardial perfusion with 4%
510 paraformaldehyde. The eyeballs were further subjected to PFA treatment for 1 h. The
511 eye tissues were rinsed 3 times with 0.9 % saline and dropped into 30% sucrose solution
512 till the tissues sank to the bottom. The eyeballs were embedded in OCT media and 10-
513 15- μ m thick retinal sections were cut with the help of cryostat and dipped into ice-cold
514 ethanol for tissue permeabilization for antibody treatment. The sections were blocked
515 with serum treatment and subjected to incubation with primary antibodies (1:300). The
516 eye sections were subsequently incubated with secondary antibodies (1:400 in Tris
517 phosphate saline buffer) as indicated for 1 hour in the dark room and mounted using
518 antifade media containing DAPI for nuclear staining. The images were obtained using
519 Carl Zeiss microscopes and data analysed. PFA fixed human eyes were similarly
520 washed with 0.9% saline and embedded in OCT media. The sections were cut using
521 cryostat, stained with crystalline antibodies and images captured as described above.

522

523

524 **5. Conclusion**

525 In present study, we aimed to investigate shared retinal protein components from
526 experimental glaucoma and human glaucoma subjects. We identified that
527 experimentally elevated IOP in rat retinas shared components of several tissue stresses
528 and adaptive or neuroprotective responses that were also identifiable in post-mortem
529 retinal tissue from human glaucoma subjects. Notably, many biochemical networks
530 such as modulation of cholesterol transport proteins and classical complement
531 activation were uniquely affected in the human eyes. It is important to emphasise that
532 the responses detected in rat retinas were caused by IOP increase alone without any
533 underlying manifest neurodegenerative or vascular pathology. This is a limitation of
534 the current glaucoma models being used in research; nevertheless, the molecular data
535 helps to dissect various components of the glaucoma pathology as a complex
536 neurodegenerative/ vascular disorder. In addition, the proteomics data provides new
537 insights into a purely high IOP induced scenario for retinal changes, without the
538 complex interplay of aging, genetic or systemic factors and drug effects, which as
539 inevitable confounding variables in human cohort studies. Future research will
540 elucidate the individual effects of various risk factors in glaucoma and help us to better
541 understand the disease process and thereby develop new therapeutic strategies.

542

543


544 **Acknowledgments** We acknowledge funding support from the Australian Government
545 National Collaborative Research Infrastructure Scheme (NCRIS), National Health and
546 Medical Research Council (NHMRC) Australia, Ophthalmic Research Institute of
547 Australia (ORIA) and Macquarie University, NSW, Australia.

548 **Conflict of interest** All authors declare no competing financial interests in the
549 findings of this study.

550

551

Figure 1




552

553 **Figure 1** Experimental design and TMT labelling workflow of the experimental
 554 glaucoma study. Retinas from control and high IOP rats were harvested (n = 5 each).
 555 Extracted proteins from these retinas were alkylated and digested with Lys-C and
 556 Trypsin after reduction. The samples were labelled with 10 plex TMT, fractionated and
 557 analysed by LC-ESI-MS/MS on ThermoFisher Orbitrap Fusion mass spectrometer
 558 (SPS-MS3 method).

559

560




561

562 **Figure 2** (A) Heatmap (hierarchical clustering) of the log-transformed ratios of
 563 differentially expressed proteins from retinal samples (glaucoma vs. control). Red and
 564 green colour-coding indicate relative increase or decrease in protein abundance,

565 respectively. (B) Volcano plots representing the expression of differentially regulated
 566 proteins. The x-axis represents log₂ fold change in abundance in glaucoma versus
 567 controls. Proteins above the horizontal dotted line indicate significance ≤ 0.05 . Samples
 568 that lie in upper and outer quadrants are considered as differentially regulated in
 569 glaucomatous conditions. Dots with labelling are the top 50 up and down regulated
 570 proteins, respectively. (C) Fold changes of the top 50 up (red colour) and down (green
 571 colour) regulated proteins in rat retina with glaucoma are indicated in the graph. (D)
 572 Network generated with the top 50 up- and down- regulated proteins using Cytoscape
 573 String plugin. The orange and green colours represent the up- and down-regulated
 574 proteins respectively.
 575

Figure 3




576
 577 **Figure 3** Functional interaction networks analysed by the String Cytoscape plugin. 143
 578 differentially expressed proteins were in generated pathways. Network nodes are
 579 labelled with gene symbols, and the corresponding fold changes are indicated below
 580 using mini heatmaps. The enriched networks such as oxidoreductase activity, G-protein

581 signalling, cytoskeletal organisation, Ca²⁺ binding, oxidative phosphorylation, RNA
 582 metabolism are shown (red- upregulated; Green- downregulated).

583

Figure 4



584


585 **Figure 4** The top 30 canonical pathways enriched from IPA analysis of differentially
 586 regulated proteins in retina (glaucoma vs. control). Heatmap of the log transformed
 587 abundance ratios representing top disease related biological pathways and differentially
 588 affected associated markers in the retina in high IOP exposed eyes. The red colour
 589 indicates the significance of the functional enrichment. Proteins in specific pathways
 590 are also listed

591

Figure 5A

| Description | Gene ID | Rat | Human |
|--------------------------------------------------------|----------|-------|--------|
| Beta-crystallin A2 | cryba2 | -3.62 | -17.96 |
| Beta-crystallin A3 | cryba1 | -3.68 | -15.62 |
| Beta-crystallin A4 | cryba4 | -3.62 | -13.79 |
| Beta-crystallin B2 | crybb2 | -3.21 | -13.23 |
| Beta-crystallin B1 | crybb1 | -2.79 | -11.79 |
| Gamma-crystallin 5 | cryg5 | -3.17 | -11.56 |
| Alpha-crystallin A chain | cryaa | -2.33 | -8.26 |
| Alpha-crystallin B chain | cryab | -4.27 | -7.43 |
| Beta-crystallin B3 | crybb3 | -3.42 | -6.99 |
| Fibrillin-1 | fbn1 | -3.32 | -5.67 |
| Microfibrillar-associated protein 2 | mfap2 | -3.19 | -4.13 |
| Retinal dehydrogenase 1 | aldh1a1 | -1.57 | -2.35 |
| Metallothionein-3 | mt3 | -1.60 | -2.27 |
| Anion exchange protein 2 | slc4a2 | 1.32 | -2.09 |
| Glutathione S-transferase Mu 1 | gstm1 | -1.52 | -1.95 |
| Tropomyosin alpha-1 chain | tpm1 | -1.71 | -1.87 |
| Calcium-regulated heat-stable protein 1 | carhsp1 | -2.03 | -1.87 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | uchl1 | -1.40 | -1.73 |
| Protein S100-A4 | s100a4 | -1.88 | -1.69 |
| Myotrophin | mtpn | -1.43 | -1.68 |
| Protein prune homolog 2 | prune2 | 1.48 | -1.68 |
| Hyaluronan and proteoglycan link protein 1 | hapln1 | -1.82 | -1.67 |
| Annexin A6 | anxa6 | -1.51 | -1.63 |
| Caveolae-associated protein 2 | sdpr | -1.35 | -1.60 |
| Fatty acid-binding protein 5 | fabp5 | -1.65 | -1.58 |
| Transcription elongation factor A protein-like 6 | tcea16 | -1.57 | -1.55 |
| Ubiquitin-conjugating enzyme E2 L3 | ube2l3 | -1.40 | -1.53 |
| Prothymosin alpha | ptma | -1.44 | -1.52 |
| Neuroblast differentiation-associated protein AHNAK | ahnak | -1.94 | -1.48 |
| Ras GTPase-activating-like protein IQGAP2 | iqgap2 | -2.47 | -1.47 |
| Vitrin | vit | -2.65 | -1.45 |
| Transcription elongation factor A protein-like 5 | tcea15 | -1.52 | -1.45 |
| Methanethiol oxidase | selenbp1 | -1.40 | -1.44 |
| Glia maturation factor beta | gmfb | -1.32 | -1.44 |
| Protein S100-A10 | s100a10 | -2.00 | -1.43 |
| Astrocytic phosphoprotein PEA-15 | pea15 | -1.30 | -1.43 |
| Glutathione S-transferase Mu 2 | gstm2 | -2.35 | -1.42 |
| Enolase-phosphatase E1 | enoph1 | -1.44 | -1.41 |
| Calcium-binding mitochondrial carrier protein Aralar2 | slc25a13 | 1.30 | -1.40 |
| Aldose reductase | akr1b1 | -1.87 | -1.39 |
| Annexin A1 | anxa1 | -3.79 | -1.35 |
| Gasdermin-E | dfna5 | 1.52 | -1.34 |
| Complexin-2 | cplx2 | -1.67 | -1.34 |
| Fibrinogen gamma chain | fgg | 1.58 | -1.33 |
| C-reactive protein | crp | 1.37 | -1.32 |
| Glutathione synthetase | gss | -1.54 | -1.31 |
| Peptidyl-prolyl cis-trans isomerase FKBP3 | fkbp3 | -1.31 | -1.30 |
| Heat shock factor-binding protein 1 | hsbp1 | -1.48 | 1.31 |
| Coronin-1A | coro1a | 1.51 | 1.32 |
| Retinoschelin | rs1 | 1.44 | 1.34 |
| Carbonic anhydrase 1 | ca1 | 1.46 | 1.34 |
| Valacyclovir hydrolase | bphl | -1.47 | 1.39 |
| Enhancer of rudimentary homolog | erh | -1.43 | 1.40 |
| SPARC-like protein 1 | sparcl1 | -2.13 | 1.41 |
| Guanine nucleotide-binding protein G | gnb3 | 1.31 | 1.48 |
| Proteasome activator complex subunit 2 | psme2 | -1.84 | 1.50 |
| C-terminal-binding protein 2 | ctbp2 | 1.32 | 1.56 |
| Dmx-like protein 2 | dmx2 | 1.32 | 1.56 |
| Tropomyosin alpha-3 chain | tpm3 | -1.34 | 1.60 |
| Cystatin-C | cst3 | -2.66 | 1.70 |
| Neuronal membrane glycoprotein MG-b | gpm6b | 1.40 | 2.06 |
| Cell cycle exit and neuronal differentiation protein 1 | caud1 | -1.30 | 2.09 |
| Neuronal membrane glycoprotein MG-a | gpm6a | 1.38 | 2.16 |
| Apolipoprotein E | apoe | -1.99 | 2.40 |
| Synaptic vesicle glycoprotein 2A | sv2a | 1.31 | 2.48 |

Figure 5B



592

593

594 **Figure 5 (A)** Heatmap generated with the common regulated proteins in both rat and
 595 human retina with glaucoma. Red and green colours indicate relative increase or
 596 decrease (glaucoma vs control) in protein abundance, respectively. **(B)** The bar graphs
 597 indicated 4 main pathways in which these common proteins are involved. The
 598 regulation patterns of proteins are also revealed.

599

600




Figure 6

601

602 **Figure 6 (A)** Immunostaining of the retinal sections from controlled and glaucoma rats
603 illustrating β 2-Crystallin (Green – Alexa Fluor 488), β 3-Crystallin (Green - FITC)
604 and α B Crystallin (Red – Cy3) expression (Blue-DAPI) (n=3 each). **(B)**
605 Immunostaining of the retinal sections from controlled and glaucoma human
606 postmortem tissues illustrating β 2-Crystallin (Green – Alexa Fluor 488), β 3-
607 Crystallin (Green - FITC) and α B Crystallin (Red – Cy3) expression (Blue-DAPI) (n=3
608 each). Scale=50 μ m.

609

610 Tables

611 **Table 1** The list of proteins identified in the control and glaucoma retinal samples,
612 including differentially expressed proteins identified from pairwise comparison test of
613 Glaucoma vs. Control (student t-test, p-value ≤ 0.05 and ≥ 1.2 -fold difference).
614 (<https://data.mendeley.com/research-data/>)

615

616

617

618 **References:**

619

- 620 Alqawlaq S, Huzil JT, Ivanova MV, Foldvari M. 2012. Challenges in neuroprotective nanomedicine
621 development: progress towards noninvasive gene therapy of glaucoma. *Nanomedicine* 7:1067-1083.
- 622 Anders F, Teister J, Funke S, Pfeiffer N, Grus F, Solon T, Prokosch V. 2017. Proteomic profiling
623 reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model.
624 *Graefes Arch Clin Exp Ophthalmol* 255:1395-1407.
- 625 Bhattacharya SK, Crabb JS, Bonilha VL, Gu X, Takahara H, Crabb JW. 2006. Proteomics implicates
626 peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. *Invest*
627 *Ophthalmol Vis Sci* 47:2508-14.
- 628 Cai X, Du J, Liu Y, Xia W, Liu J, Zou M, Wang Y, Wang M, Su H, Xu D. 2013. Identification and
629 characterization of receptor-interacting protein 2 as a TNFR-associated factor 3 binding partner. *Gene*
630 517:205-11.
- 631 Chick JM, Munger SC, Simecek P, Huttlin EL, Choi K, Gatti DM, Raghupathy N, Svenson KL,
632 Churchill GA, Gygi SP. 2016. Defining the consequences of genetic variation on a proteome-wide
633 scale. *Nature* 534:500-505.
- 634 Chitranshi N, Dheer Y, Abbasi M, You Y, Graham SL, Gupta V. 2018a. Glaucoma Pathogenesis and
635 Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects. *Curr*
636 *Neuropharmacol* 16:1018-1035.
- 637 Chitranshi N, Dheer Y, Mirzaei M, Wu Y, Salekdeh GH, Abbasi M, Gupta V, Vander Wall R, You Y,
638 Graham SL, Gupta V. 2018b. Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to
639 Improved Retinal Ganglion Cell Neuroprotection. *Mol Ther*.
- 640 Chitranshi N, Dheer Y, Mirzaei M, Wu Y, Salekdeh GH, Abbasi M, Gupta V, Vander Wall R, You Y,
641 Graham SL, Gupta V. 2019. Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to
642 Improved Retinal Ganglion Cell Neuroprotection. *Mol Ther* 27:424-441.
- 643 Chrysostomou V, Rezanian F, Trounce IA, Crowston JG. 2013. Oxidative stress and mitochondrial
644 dysfunction in glaucoma. *Curr Opin Pharmacol* 13:12-5.
- 645 Clark AF, Miggans ST, Wilson K, Browder S, McCartney MD. 1995. Cytoskeletal changes in cultured
646 human glaucoma trabecular meshwork cells. *J Glaucoma* 4:183-8.
- 647 Dismuke WM, McKay BS, Stamer WD. 2012. Myocilin, a component of a membrane-associated
648 protein complex driven by a homologous Q-SNARE domain. *Biochemistry* 51:3606-13.
- 649 Elias JE, Gygi SP. 2010. Target-Decoy Search Strategy for Mass Spectrometry-Based Proteomics. In
650 Hubbard SJ, Jones AR, editor^editors. *Proteome Bioinformatics*. Totowa, NJ: Humana Press, p 55-71.
- 651 Frost LS, Mitchell CH, Boesze-Battaglia K. 2014. Autophagy in the eye: implications for ocular cell
652 health. *Exp Eye Res* 124:56-66.
- 653 Funke S, Perumal N, Beck S, Gabel-Scheurich S, Schmelter C, Teister J, Gerbig C, Gramlich OW,
654 Pfeiffer N, Grus FH. 2016. Glaucoma related Proteomic Alterations in Human Retina Samples. *Sci Rep*
655 6:29759.
- 656 Gupta V, You Y, Li J, Gupta V, Golzan M, Klistorner A, van den Buuse M, Graham S. 2014. BDNF
657 impairment is associated with age-related changes in the inner retina and exacerbates experimental
658 glaucoma. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1842:1567-1578.
- 659 Hoare MJ, Grierson I, Brotchie D, Pollock N, Cracknell K, Clark AF. 2009. Cross-linked actin
660 networks (CLANs) in the trabecular meshwork of the normal and glaucomatous human eye in situ.
661 *Invest Ophthalmol Vis Sci* 50:1255-63.
- 662 Horita S, Simsek E, Simsek T, Yildirim N, Ishiura H, Nakamura M, Satoh N, Suzuki A, Tsukada H,
663 Mizuno T, Seki G, Tsuji S, Nangaku M. 2018. SLC4A4 compound heterozygous mutations in exon-
664 intron boundary regions presenting with severe proximal renal tubular acidosis and extrarenal
665 symptoms coexisting with Turner's syndrome: a case report. *BMC Med Genet* 19:103.
- 666 Hüttemann M, Lee I, Samavati L, Yu H, Doan JW. 2007. Regulation of mitochondrial oxidative
667 phosphorylation through cell signaling. *Biochimica et Biophysica Acta (BBA) - Molecular Cell*
668 *Research* 1773:1701-1720.
- 669 Huttlin EL, Ting L, Bruckner RJ, Gebreab F, Gygi MP, Szpyt J, Tam S, Zarraga G, Colby G, Baltier K.
670 2015. The BioPlex network: a systematic exploration of the human interactome. *Cell* 162:425-440.
- 671 Ishikawa K, Yoshida S, Kadota K, Nakamura T, Niuro H, Arakawa S, Yoshida A, Akashi K, Ishibashi
672 T. 2010. Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygen-
673 induced retinopathy. *Invest Ophthalmol Vis Sci* 51:4307-19.
- 674 Jacobsen AV, Murphy JM. 2017. The secret life of kinases: insights into non-catalytic signalling
675 functions from pseudokinases. *Biochem Soc Trans* 45:665-681.

676 Job R, Raja V, Grierson I, Currie L, O'Reilly S, Pollock N, Knight E, Clark AF. 2010. Cross-linked
677 actin networks (CLANs) are present in lamina cribrosa cells. *Br J Ophthalmol* 94:1388-92.
678 Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson
679 MR, Gordon MO. 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that
680 topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
681 *Arch Ophthalmol* 120:701-13; discussion 829-30.
682 Kim KY, Perkins GA, Shim MS, Bushong E, Alcasid N, Ju S, Ellisman MH, Weinreb RN, Ju WK.
683 2015. DRP1 inhibition rescues retinal ganglion cells and their axons by preserving mitochondrial
684 integrity in a mouse model of glaucoma. *Cell Death Dis* 6:e1839.
685 Komatsu M, Wang QJ, Holstein GR, Friedrich VL, Jr., Iwata J, Kominami E, Chait BT, Tanaka K,
686 Yue Z. 2007. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and
687 the prevention of axonal degeneration. *Proc Natl Acad Sci U S A* 104:14489-94.
688 Kong GYX, Van Bergen NJ, Trounce IA, Crowston JG. 2009. Mitochondrial Dysfunction and
689 Glaucoma. *Journal of Glaucoma* 18:93-100.
690 Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M. 2014. Minimal, encapsulated proteomic-sample
691 processing applied to copy-number estimation in eukaryotic cells. *Nature methods* 11:319-324.
692 Launay N, Goudeau B, Kato K, Vicart P, Lilienbaum A. 2006. Cell signaling pathways to alphaB-
693 crystallin following stresses of the cytoskeleton. *Exp Cell Res* 312:3570-84.
694 Lee D, Kim KY, Shim MS, Kim SY, Ellisman MH, Weinreb RN, Ju WK. 2014. Coenzyme Q10
695 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury. *Apoptosis*
696 19:603-14.
697 Lee S, Van Bergen NJ, Kong GY, Chrysostomou V, Waugh HS, O'Neill EC, Crowston JG, Trounce
698 IA. 2011. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. *Exp Eye Res*
699 93:204-12.
700 Levi M, van der Poll T. 2010. Inflammation and coagulation. *Crit Care Med* 38:S26-34.
701 Liang XH, Sun H, Nichols JG, Allen N, Wang S, Vickers TA, Shen W, Hsu CW, Crooke ST. 2018.
702 COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of
703 oligonucleotides from endocytic pathways. *Nucleic Acids Res* 46:10225-10245.
704 Liedtke T, Schwamborn JC, Schröer U, Thanos S. 2007. Elongation of Axons during Regeneration
705 Involves Retinal Crystallin β 2 (crybb2). *Molecular & Cellular Proteomics* 6:895-907.
706 Liu Y, Allingham RR, Qin X, Layfield D, Dellinger AE, Gibson J, Wheeler J, Ashley-Koch AE,
707 Stamer WD, Hauser MA. 2013. Gene expression profile in human trabecular meshwork from patients
708 with primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 54:6382-9.
709 Manca F, Pincet F, Truskinovsky L, Rothman JE, Foret L, Caruel M. 2019. SNARE machinery is
710 optimized for ultrafast fusion. *Proc Natl Acad Sci U S A* 116:2435-2442.
711 McAlister GC, Huttlin EL, Haas W, Ting L, Jedrychowski MP, Rogers JC, Kuhn K, Pike I, Grothe RA,
712 Blethrow JD. 2012. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues
713 with isobaric masses. *Analytical chemistry* 84:7469-7478.
714 McAlister GC, Nusinow DP, Jedrychowski MP, Wühr M, Huttlin EL, Erickson BK, Rad R, Haas W,
715 Gygi SP. 2014. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential
716 expression across cancer cell line proteomes. *Analytical chemistry* 86:7150-7158.
717 McKay BS, Congrove NR, Johnson AA, Dismuke WM, Bowen TJ, Stamer WD. 2013. A role for
718 myocilin in receptor-mediated endocytosis. *PLoS One* 8:e82301.
719 McMonnies CW. 2017. Glaucoma history and risk factors. *J Optom* 10:71-78.
720 Mirzaei M, Deng L, Gupta VB, Graham S, Gupta V. 2020. Complement pathway in Alzheimer's
721 pathology and retinal neurodegenerative disorders - the road ahead. *Neural Regen Res* 15:257-258.
722 Mirzaei M, Gupta VB, Chick JM, Greco TM, Wu Y, Chitranshi N, Wall RV, Hone E, Deng L, Dheer
723 Y, Abbasi M, Rezaeian M, Braidy N, You Y, Salekdeh GH, Haynes PA, Molloy MP, Martins R,
724 Cristea IM, Gygi SP, Graham SL, Gupta VK. 2017a. Age-related neurodegenerative disease associated
725 pathways identified in retinal and vitreous proteome from human glaucoma eyes. *Sci Rep* 7:12685.
726 Mirzaei M, Pascovici D, Wu JX, Chick J, Wu Y, Cooke B, Haynes P, Molloy MP. 2017b. TMT One-
727 Stop Shop: From Reliable Sample Preparation to Computational Analysis Platform. In Keerthikumar S,
728 Mathivanan S, editor^editors. *Proteome Bioinformatics*. New York, NY: Springer New York, p 45-66.
729 Moreno MC, Campanelli J, Sande P, Sáenz DA, Keller Sarmiento MI, Rosenstein RE. 2004. Retinal
730 Oxidative Stress Induced by High Intraocular Pressure. *Free Radical Biology and Medicine* 37:803-
731 812.
732 Munemasa Y, Kitaoka Y, Kuribayashi J, Ueno S. 2010. Modulation of mitochondria in the axon and
733 soma of retinal ganglion cells in a rat glaucoma model. *J Neurochem* 115:1508-19.
734 Piri N, Song M, Kwong JMK, Caprioli J. 2007. Modulation of alpha and beta crystallin expression in
735 rat retinas with ocular hypertension-induced ganglion cell degeneration. *Brain Research* 1141:1-9.

736 Porter K, Nallathambi J, Lin Y, Liton PB. 2013. Lysosomal basification and decreased autophagic flux
737 in oxidatively stressed trabecular meshwork cells: implications for glaucoma pathogenesis. *Autophagy*
738 9:581-94.

739 Prokosch V, Schallenberg M, Thanos S. 2013. Crystallins Are Regulated Biomarkers for Monitoring
740 Topical Therapy of Glaucomatous Optic Neuropathy. *PLOS ONE* 8:e49730.

741 Stowell C, Arbogast B, Cioffi G, Burgoyne C, Zhou A. 2011. Retinal proteomic changes following
742 unilateral optic nerve transection and early experimental glaucoma in non-human primate eyes. *Exp*
743 *Eye Res* 93:13-28.

744 Swarup G, Sayyad Z. 2018. Altered Functions and Interactions of Glaucoma-Associated Mutants of
745 Optineurin. *Front Immunol* 9:1287.

746 Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A,
747 Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. 2015. STRING v10: protein-protein
748 interaction networks, integrated over the tree of life. *Nucleic Acids Research* 43:D447-D452.

749 Tezel G. 2013. A proteomics view of the molecular mechanisms and biomarkers of glaucomatous
750 neurodegeneration. *Prog Retin Eye Res* 35:18-43.

751 Tezel G. 2014. A decade of proteomics studies of glaucomatous neurodegeneration. *Proteomics Clin*
752 *Appl* 8:154-67.

753 Tezel G, Seigel GM, Wax MB. 1998. Autoantibodies to small heat shock proteins in glaucoma.
754 *Investigative Ophthalmology & Visual Science* 39:2277-2287.

755 Tezel G, Yang X, Cai J. 2005. Proteomic identification of oxidatively modified retinal proteins in a
756 chronic pressure-induced rat model of glaucoma. *Invest Ophthalmol Vis Sci* 46:3177-87.

757 Tian H, Wang L, Cai R, Zheng L, Guo L. 2014. Identification of protein network alterations upon
758 retinal ischemia-reperfusion injury by quantitative proteomics using a *Rattus norvegicus* model. *PLoS*
759 *One* 9:e116453.

760 Wang DY, Ray A, Rodgers K, Ergorul C, Hyman BT, Huang W, Grosskreutz CL. 2010. Global gene
761 expression changes in rat retinal ganglion cells in experimental glaucoma. *Invest Ophthalmol Vis Sci*
762 51:4084-95.

763 Wessel D, Flügge UI. 1984. A method for the quantitative recovery of protein in dilute solution in the
764 presence of detergents and lipids. *Analytical biochemistry* 138:141-143.

765 Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW.
766 2017. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. *Science*
767 355:756-760.

768 You Y, Gupta VK, Li JC, Al-Adawy N, Klistorner A, Graham SL. 2014. FTY720 Protects Retinal
769 Ganglion Cells in Experimental Glaucoma FTY720 Protects RGCs. *Investigative Ophthalmology &*
770 *Visual Science* 55:3060-3066.

771 You Y, Thie J, Klistorner A, Gupta VK, Graham SL. 2012. Normalization of visual evoked potentials
772 using underlying electroencephalogram levels improves amplitude reproducibility in rats. *Invest*
773 *Ophthalmol Vis Sci* 53:1473-8.

774 Yu DH, Zhang X, Wang H, Zhang L, Chen H, Hu M, Dong Z, Zhu G, Qian Z, Fan J, Su X, Xu Y,
775 Zheng L, Dong H, Yin X, Ji Q, Ji J. 2014. The essential role of TNIK gene amplification in gastric
776 cancer growth. *Oncogenesis* 2:e89.

777 Zagajewska K, Piatkowska M, Goryca K, Balabas A, Kluska A, Paziewska A, Pospiech E, Grabska-
778 Liberek I, Hennig EE. 2018. GWAS links variants in neuronal development and actin remodeling
779 related loci with pseudoexfoliation syndrome without glaucoma. *Exp Eye Res* 168:138-148.

780

781